United States Pharmaceuticals

Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics experienced significant insider trading activity over the past ninety days, characterized by fifty-six sell transactions totaling approximately 4.6 million dollars in net value. Executives consistently utilized planned divestments despite a twenty-eight percent stock decline. These sales occurred following a positive earnings report, reflecting ongoing liquidity events for key personnel within the healthcare firm.
Ticker: CORT Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Corcept Therapeutics Incorporated. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
WILSON JAMES N Non-Executive Director
Transaction date
Planned sale
Price
307.23
Quantity 52,480 +41.5%
Value US$218,573
WILSON JAMES N Non-Executive Director
Transaction date
Planned sale
Price
312.36
Quantity 99,000 +37.4%
Value US$950,330
WILSON JAMES N Non-Executive Director
Transaction date
Planned sale
Price
403.56
Quantity 33,085 -5.3%
Value US$2,703,156
Vieira Roberto Wandenkolk President, Oncology Officer
Transaction date
Planned sale
Price
116.59
Quantity 5,147 -56.6%
Value US$600,063
Vieira Roberto Wandenkolk President, Oncology Officer
Transaction date
Planned sale
Price
115.73
Quantity 2,086 -18.7%
Value US$241,412
Vieira Roberto Wandenkolk President, Oncology Officer
Transaction date
Planned sale
Price
114.52
Quantity 1,100 -9.0%
Value US$125,973
3.4
Lyon Joseph Douglas See Remarks Officer
Transaction date
Planned sale
Price
116.54
Quantity 4,744 -45.5%
Value US$552,869
3.4
Lyon Joseph Douglas See Remarks Officer
Transaction date
Planned sale
Price
115.70
Quantity 4,446 -29.9%
Value US$514,389
3.5
Maduck Sean See Remarks Officer
Transaction date
Planned sale
Price
116.55
Quantity 8,744 -46.8%
Value US$1,019,143
3.5
Maduck Sean See Remarks Officer
Transaction date
Planned sale
Price
116.12
Quantity 15,843 -45.9%
Value US$1,839,741
3.4
Lyon Joseph Douglas See Remarks Officer
Transaction date
Planned sale
Price
115.40
Quantity 810 -12.5%
Value US$93,473
3.5
Maduck Sean See Remarks Officer
Transaction date
Planned sale
Price
115.54
Quantity 413 -4.0%
Value US$47,717
3.4
Lyon Joseph Douglas Officer Officer
Transaction date
Proposed sale
Price
115.23
Quantity 10,000
Value US$1,152,300
Vieira Roberto Wandenkolk President, Oncology Officer
Transaction date
Planned sale
Price
100.82
Quantity 296 -7.0%
Value US$29,843
WILSON JAMES N Non-Executive Director
Transaction date
Planned sale
Price
111.70
Quantity 2,800 -0.3%
Value US$312,771
WILSON JAMES N Non-Executive Director
Transaction date
Planned sale
Price
110.84
Quantity 400 -0.0%
Value US$44,335
WILSON JAMES N Non-Executive Director
Transaction date
Planned sale
Price
110.27
Quantity 6,800 -0.6%
Value US$749,835
WILSON JAMES N Director Non-Executive Director
Transaction date
Proposed sale
Price
111.48
Quantity 30,000
Value US$3,344,400
3.4
Lyon Joseph Douglas See Remarks Officer
Transaction date
Planned sale
Price
114.12
Quantity 2,188 -27.8%
Value US$249,686
3.4
Lyon Joseph Douglas See Remarks Officer
Transaction date
Planned sale
Price
113.32
Quantity 7,812 -49.8%
Value US$885,261
3.4
Lyon Joseph Douglas Officer Officer
Transaction date
Proposed sale
Price
113.44
Quantity 10,000
Value US$1,134,424
Vieira Roberto Wandenkolk President, Oncology Officer
Transaction date
Planned sale
Price
115.44
Quantity 1,225 -22.4%
Value US$141,413
Vieira Roberto Wandenkolk President, Oncology Officer
Transaction date
Planned sale
Price
114.58
Quantity 5,621 -50.7%
Value US$644,042
Vieira Roberto Wandenkolk President, Oncology Officer
Transaction date
Planned sale
Price
113.72
Quantity 1,606 -12.7%
Value US$182,632
Vieira Roberto Wandenkolk President, Oncology Officer
Transaction date
Planned sale
Price
112.40
Quantity 974 -7.1%
Value US$109,474
Vieira Roberto Wandenkolk President, Oncology Officer
Transaction date
Planned sale
Price
111.37
Quantity 1,537 -10.1%
Value US$171,181
Vieira Roberto Wandenkolk President, Oncology Officer
Transaction date
Planned sale
Price
110.70
Quantity 23,770 -61.0%
Value US$2,631,349
Vieira Roberto Wandenkolk President, Oncology Officer
Transaction date
Planned sale
Price
109.35
Quantity 23,600 -37.7%
Value US$2,580,674
Vieira Roberto Wandenkolk Officer Officer
Transaction date
Proposed sale
Price
110.76
Quantity 75,295
Value US$8,339,418
3.5
Maduck Sean See Remarks Officer
Transaction date
Planned sale
Price
115.61
Quantity 2,281 -19.0%
Value US$263,711
3.5
Maduck Sean See Remarks Officer
Transaction date
Planned sale
Price
114.71
Quantity 10,989 -47.7%
Value US$1,260,568
3.5
Maduck Sean See Remarks Officer
Transaction date
Planned sale
Price
113.94
Quantity 11,730 -33.8%
Value US$1,336,459
Park Kimberly Non-Executive Director
Transaction date
Sale
Price
122.55
Quantity 26,685 -100.0%
Value US$3,270,169
KIMBERLY PARK Director Non-Executive Director
Transaction date
Proposed sale
Price
122.55
Quantity 26,685
Value US$3,270,169
3.5
Maduck Sean See Remarks Officer
Transaction date
Planned sale
Price
126.06
Quantity 5,870 -37.6%
Value US$739,965
3.5
Maduck Sean See Remarks Officer
Transaction date
Planned sale
Price
125.47
Quantity 25,085 -61.6%
Value US$3,147,355
3.5
Maduck Sean Officer Officer
Transaction date
Proposed sale
Price
125.58
Quantity 175,000
Value US$21,976,448
2.4
MAHONEY DAVID L Non-Executive Director
Transaction date
Planned sale
Price
119.64
Quantity 400 -0.0%
Value US$47,855
2.4
MAHONEY DAVID L Non-Executive Director
Transaction date
Planned sale
Price
118.88
Quantity 7,055 -0.6%
Value US$838,710
2.4
MAHONEY DAVID L Non-Executive Director
Transaction date
Planned sale
Price
118.24
Quantity 91,167 -7.4%
Value US$10,779,367
2.4
MAHONEY DAVID L Non-Executive Director
Transaction date
Planned sale
Price
117.47
Quantity 4,984 -0.4%
Value US$585,478
2.4
MAHONEY DAVID L Director Non-Executive Director
Transaction date
Proposed sale
Price
117.37
Quantity 103,606
Value US$12,160,257
3.7
Robb Gary Charles Chief Business Officer Officer
Transaction date
Sale
Price
116.26
Quantity 10,000 -20.1%
Value US$1,162,572
3.7
Robb Gary Charles Officer Officer
Transaction date
Proposed sale
Price
116.26
Quantity 10,000
Value US$1,162,572
WILSON JAMES N Non-Executive Director
Transaction date
Planned sale
Price
112.64
Quantity 2,279 -0.2%
Value US$256,706
WILSON JAMES N Non-Executive Director
Transaction date
Planned sale
Price
111.44
Quantity 4,668 -0.4%
Value US$520,214
WILSON JAMES N Non-Executive Director
Transaction date
Planned sale
Price
110.49
Quantity 3,053 -0.3%
Value US$337,341
3.5
Maduck Sean See Remarks Officer
Transaction date
Planned sale
Price
114.49
Quantity 3,664 -27.3%
Value US$419,491
3.5
Maduck Sean See Remarks Officer
Transaction date
Planned sale
Price
114.52
Quantity 1,031 -9.6%
Value US$118,068
2.5
Guyer William Chief Development Officer Officer
Transaction date
Planned sale
Price
114.04
Quantity 4,770 -54.5%
Value US$543,957
2.5
Guyer William Chief Development Officer Officer
Transaction date
Planned sale
Price
113.18
Quantity 11,530 -56.8%
Value US$1,304,933
2.5
Guyer William Chief Development Officer Officer
Transaction date
Planned sale
Price
113.12
Quantity 3,700 -48.1%
Value US$418,562
2.5
Guyer William Officer Officer
Transaction date
Proposed sale
Price
112.80
Quantity 20,000
Value US$2,256,000
3.5
Maduck Sean See Remarks Officer
Transaction date
Planned sale
Price
114.70
Quantity 20,305 -67.5%
Value US$2,329,075
3.4
Lyon Joseph Douglas See Remarks Officer
Transaction date
Sale
Price
114.16
Quantity 1,540 -21.9%
Value US$175,806
3.4
Lyon Joseph Douglas Officer Officer
Transaction date
Proposed sale
Price
114.16
Quantity 1,540
Value US$175,806
Mokari Atabak Chief Financial Officer Officer
Transaction date
Planned sale
Price
120.67
Quantity 1,001 -5.8%
Value US$120,796
Mokari Atabak Chief Financial Officer Officer
Transaction date
Planned sale
Price
119.95
Quantity 8,103 -32.1%
Value US$971,939
Mokari Atabak Chief Financial Officer Officer
Transaction date
Planned sale
Price
118.73
Quantity 4,783 -15.9%
Value US$567,908
Mokari Atabak Chief Financial Officer Officer
Transaction date
Planned sale
Price
117.93
Quantity 8,267 -21.6%
Value US$974,951
Mokari Atabak Chief Financial Officer Officer
Transaction date
Planned sale
Price
116.96
Quantity 7,089 -15.6%
Value US$829,102
Mokari Atabak Chief Financial Officer Officer
Transaction date
Planned sale
Price
115.87
Quantity 14,222 -23.9%
Value US$1,647,859
Mokari Atabak Chief Financial Officer Officer
Transaction date
Planned sale
Price
114.96
Quantity 15,477 -20.6%
Value US$1,779,237
Mokari Atabak Chief Financial Officer Officer
Transaction date
Planned sale
Price
113.18
Quantity 4,700 -5.9%
Value US$531,941
Mokari Atabak Chief Financial Officer Officer
Transaction date
Planned sale
Price
110.95
Quantity 600 -0.7%
Value US$66,570
Mokari Atabak Chief Financial Officer Officer
Transaction date
Planned sale
Price
110.03
Quantity 2,202 -2.7%
Value US$242,282
Mokari Atabak Chief Financial Officer Officer
Transaction date
Planned sale
Price
108.46
Quantity 400 -0.5%
Value US$43,384
Mokari Atabak Chief Financial Officer Officer
Transaction date
Planned sale
Price
106.96
Quantity 8,956 -9.7%
Value US$957,892
Mokari Atabak Chief Financial Officer Officer
Transaction date
Planned sale
Price
105.54
Quantity 4,200 -4.4%
Value US$443,248
Mokari Atabak Officer Officer
Transaction date
Proposed sale
Price
114.71
Quantity 40,000
Value US$4,588,556
WILSON JAMES N Non-Executive Director
Transaction date
Planned sale
Price
89.49
Quantity 1,978 -0.2%
Value US$177,007
WILSON JAMES N Non-Executive Director
Transaction date
Planned sale
Price
88.81
Quantity 2,974 -0.3%
Value US$264,122
WILSON JAMES N Non-Executive Director
Transaction date
Planned sale
Price
87.74
Quantity 3,969 -0.4%
Value US$348,223
WILSON JAMES N Non-Executive Director
Transaction date
Planned sale
Price
86.78
Quantity 1,079 -0.1%
Value US$93,633
Mokari Atabak Chief Financial Officer Officer
Transaction date
Planned sale
Price
89.43
Quantity 101 -0.6%
Value US$9,032
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-10-16 2026-10-15 PlS Planned sale
WILSON JAMES N
Non-Executive Director
52,480 +41.5%
307.23
US$218,573 		52,480 +41.5% 307.23 US$218,573
2026-10-16 2026-10-15 PlS Planned sale
WILSON JAMES N
Non-Executive Director
99,000 +37.4%
312.36
US$950,330 		99,000 +37.4% 312.36 US$950,330
2026-10-16 2026-10-15 PlS Planned sale
WILSON JAMES N
Non-Executive Director
33,085 -5.3%
403.56
US$2,703,156 		33,085 -5.3% 403.56 US$2,703,156
2026-10-05 2026-10-02 PlS Planned sale
Vieira Roberto Wandenkolk

President, Oncology

Officer
5,147 -56.6%
116.59
US$600,063 		5,147 -56.6% 116.59 US$600,063
2026-10-05 2026-10-02 PlS Planned sale
Vieira Roberto Wandenkolk

President, Oncology

Officer
2,086 -18.7%
115.73
US$241,412 		2,086 -18.7% 115.73 US$241,412
2026-10-05 2026-10-02 PlS Planned sale
Vieira Roberto Wandenkolk

President, Oncology

Officer
1,100 -9.0%
114.52
US$125,973 		1,100 -9.0% 114.52 US$125,973
2026-10-05 2026-10-02 PlS Planned sale
3.4
Lyon Joseph Douglas

See Remarks

Officer
4,744 -45.5%
116.54
US$552,869 		4,744 -45.5% 116.54 US$552,869
2026-10-05 2026-10-02 PlS Planned sale
3.4
Lyon Joseph Douglas

See Remarks

Officer
4,446 -29.9%
115.70
US$514,389 		4,446 -29.9% 115.70 US$514,389
2026-10-05 2026-10-02 PlS Planned sale
3.5
Maduck Sean

See Remarks

Officer
8,744 -46.8%
116.55
US$1,019,143 		8,744 -46.8% 116.55 US$1,019,143
2026-10-05 2026-10-02 PlS Planned sale
3.5
Maduck Sean

See Remarks

Officer
15,843 -45.9%
116.12
US$1,839,741 		15,843 -45.9% 116.12 US$1,839,741
2026-10-05 2026-10-01 PlS Planned sale
3.4
Lyon Joseph Douglas

See Remarks

Officer
810 -12.5%
115.40
US$93,473 		810 -12.5% 115.40 US$93,473
2026-10-05 2026-10-01 PlS Planned sale
3.5
Maduck Sean

See Remarks

Officer
413 -4.0%
115.54
US$47,717 		413 -4.0% 115.54 US$47,717
2026-10-01 2026-10-01 PrS Proposed sale
3.4
Lyon Joseph Douglas

Officer

Officer
10,000
115.23
US$1,152,300 		10,000 115.23 US$1,152,300
2026-09-18 2026-09-16 PlS Planned sale
Vieira Roberto Wandenkolk

President, Oncology

Officer
296 -7.0%
100.82
US$29,843 		296 -7.0% 100.82 US$29,843
2026-09-16 2026-09-15 PlS Planned sale
WILSON JAMES N
Non-Executive Director
2,800 -0.3%
111.70
US$312,771 		2,800 -0.3% 111.70 US$312,771
2026-09-16 2026-09-15 PlS Planned sale
WILSON JAMES N
Non-Executive Director
400 -0.0%
110.84
US$44,335 		400 -0.0% 110.84 US$44,335
2026-09-16 2026-09-15 PlS Planned sale
WILSON JAMES N
Non-Executive Director
6,800 -0.6%
110.27
US$749,835 		6,800 -0.6% 110.27 US$749,835
2026-09-15 2026-09-15 PrS Proposed sale
WILSON JAMES N

Director

Non-Executive Director
30,000
111.48
US$3,344,400 		30,000 111.48 US$3,344,400
2026-09-16 2026-09-14 PlS Planned sale
3.4
Lyon Joseph Douglas

See Remarks

Officer
2,188 -27.8%
114.12
US$249,686 		2,188 -27.8% 114.12 US$249,686
2026-09-16 2026-09-14 PlS Planned sale
3.4
Lyon Joseph Douglas

See Remarks

Officer
7,812 -49.8%
113.32
US$885,261 		7,812 -49.8% 113.32 US$885,261
2026-09-14 2026-09-14 PrS Proposed sale
3.4
Lyon Joseph Douglas

Officer

Officer
10,000
113.44
US$1,134,424 		10,000 113.44 US$1,134,424
2026-09-03 2026-09-02 PlS Planned sale
Vieira Roberto Wandenkolk

President, Oncology

Officer
1,225 -22.4%
115.44
US$141,413 		1,225 -22.4% 115.44 US$141,413
2026-09-03 2026-09-02 PlS Planned sale
Vieira Roberto Wandenkolk

President, Oncology

Officer
5,621 -50.7%
114.58
US$644,042 		5,621 -50.7% 114.58 US$644,042
2026-09-03 2026-09-02 PlS Planned sale
Vieira Roberto Wandenkolk

President, Oncology

Officer
1,606 -12.7%
113.72
US$182,632 		1,606 -12.7% 113.72 US$182,632
2026-09-03 2026-09-02 PlS Planned sale
Vieira Roberto Wandenkolk

President, Oncology

Officer
974 -7.1%
112.40
US$109,474 		974 -7.1% 112.40 US$109,474
2026-09-03 2026-09-02 PlS Planned sale
Vieira Roberto Wandenkolk

President, Oncology

Officer
1,537 -10.1%
111.37
US$171,181 		1,537 -10.1% 111.37 US$171,181
2026-09-03 2026-09-02 PlS Planned sale
Vieira Roberto Wandenkolk

President, Oncology

Officer
23,770 -61.0%
110.70
US$2,631,349 		23,770 -61.0% 110.70 US$2,631,349
2026-09-03 2026-09-02 PlS Planned sale
Vieira Roberto Wandenkolk

President, Oncology

Officer
23,600 -37.7%
109.35
US$2,580,674 		23,600 -37.7% 109.35 US$2,580,674
2026-09-02 2026-09-02 PrS Proposed sale
Vieira Roberto Wandenkolk

Officer

Officer
75,295
110.76
US$8,339,418 		75,295 110.76 US$8,339,418
2026-09-03 2026-09-01 PlS Planned sale
3.5
Maduck Sean

See Remarks

Officer
2,281 -19.0%
115.61
US$263,711 		2,281 -19.0% 115.61 US$263,711
2026-09-03 2026-09-01 PlS Planned sale
3.5
Maduck Sean

See Remarks

Officer
10,989 -47.7%
114.71
US$1,260,568 		10,989 -47.7% 114.71 US$1,260,568
2026-09-03 2026-09-01 PlS Planned sale
3.5
Maduck Sean

See Remarks

Officer
11,730 -33.8%
113.94
US$1,336,459 		11,730 -33.8% 113.94 US$1,336,459
2026-08-28 2026-08-26 S Sale
Park Kimberly
Non-Executive Director
26,685 -100.0%
122.55
US$3,270,169 		26,685 -100.0% 122.55 US$3,270,169
2026-08-26 2026-08-26 PrS Proposed sale
KIMBERLY PARK

Director

Non-Executive Director
26,685
122.55
US$3,270,169 		26,685 122.55 US$3,270,169
2026-08-27 2026-08-25 PlS Planned sale
3.5
Maduck Sean

See Remarks

Officer
5,870 -37.6%
126.06
US$739,965 		5,870 -37.6% 126.06 US$739,965
2026-08-27 2026-08-25 PlS Planned sale
3.5
Maduck Sean

See Remarks

Officer
25,085 -61.6%
125.47
US$3,147,355 		25,085 -61.6% 125.47 US$3,147,355
2026-08-25 2026-08-25 PrS Proposed sale
3.5
Maduck Sean

Officer

Officer
175,000
125.58
US$21,976,448 		175,000 125.58 US$21,976,448
2026-08-20 2026-08-18 PlS Planned sale
2.4
MAHONEY DAVID L
Non-Executive Director
400 -0.0%
119.64
US$47,855 		400 -0.0% 119.64 US$47,855
2026-08-20 2026-08-18 PlS Planned sale
2.4
MAHONEY DAVID L
Non-Executive Director
7,055 -0.6%
118.88
US$838,710 		7,055 -0.6% 118.88 US$838,710
2026-08-20 2026-08-18 PlS Planned sale
2.4
MAHONEY DAVID L
Non-Executive Director
91,167 -7.4%
118.24
US$10,779,367 		91,167 -7.4% 118.24 US$10,779,367
2026-08-20 2026-08-18 PlS Planned sale
2.4
MAHONEY DAVID L
Non-Executive Director
4,984 -0.4%
117.47
US$585,478 		4,984 -0.4% 117.47 US$585,478
2026-08-18 2026-08-18 PrS Proposed sale
2.4
MAHONEY DAVID L

Director

Non-Executive Director
103,606
117.37
US$12,160,257 		103,606 117.37 US$12,160,257
2026-08-18 2026-08-17 S Sale
3.7
Robb Gary Charles

Chief Business Officer

Officer
10,000 -20.1%
116.26
US$1,162,572 		10,000 -20.1% 116.26 US$1,162,572
2026-08-17 2026-08-17 PrS Proposed sale
3.7
Robb Gary Charles

Officer

Officer
10,000
116.26
US$1,162,572 		10,000 116.26 US$1,162,572
2026-08-18 2026-08-14 PlS Planned sale
WILSON JAMES N
Non-Executive Director
2,279 -0.2%
112.64
US$256,706 		2,279 -0.2% 112.64 US$256,706
2026-08-18 2026-08-14 PlS Planned sale
WILSON JAMES N
Non-Executive Director
4,668 -0.4%
111.44
US$520,214 		4,668 -0.4% 111.44 US$520,214
2026-08-18 2026-08-14 PlS Planned sale
WILSON JAMES N
Non-Executive Director
3,053 -0.3%
110.49
US$337,341 		3,053 -0.3% 110.49 US$337,341
2026-08-18 2026-08-14 PlS Planned sale
3.5
Maduck Sean

See Remarks

Officer
3,664 -27.3%
114.49
US$419,491 		3,664 -27.3% 114.49 US$419,491
2026-08-12 2026-08-10 PlS Planned sale
3.5
Maduck Sean

See Remarks

Officer
1,031 -9.6%
114.52
US$118,068 		1,031 -9.6% 114.52 US$118,068
2026-08-12 2026-08-10 PlS Planned sale
2.5
Guyer William

Chief Development Officer

Officer
4,770 -54.5%
114.04
US$543,957 		4,770 -54.5% 114.04 US$543,957
2026-08-12 2026-08-10 PlS Planned sale
2.5
Guyer William

Chief Development Officer

Officer
11,530 -56.8%
113.18
US$1,304,933 		11,530 -56.8% 113.18 US$1,304,933
2026-08-06 2026-08-04 PlS Planned sale
2.5
Guyer William

Chief Development Officer

Officer
3,700 -48.1%
113.12
US$418,562 		3,700 -48.1% 113.12 US$418,562
2026-08-04 2026-08-04 PrS Proposed sale
2.5
Guyer William

Officer

Officer
20,000
112.80
US$2,256,000 		20,000 112.80 US$2,256,000
2026-08-05 2026-08-03 PlS Planned sale
3.5
Maduck Sean

See Remarks

Officer
20,305 -67.5%
114.70
US$2,329,075 		20,305 -67.5% 114.70 US$2,329,075
2026-08-05 2026-08-03 S Sale
3.4
Lyon Joseph Douglas

See Remarks

Officer
1,540 -21.9%
114.16
US$175,806 		1,540 -21.9% 114.16 US$175,806
2026-08-03 2026-08-03 PrS Proposed sale
3.4
Lyon Joseph Douglas

Officer

Officer
1,540
114.16
US$175,806 		1,540 114.16 US$175,806
2026-08-03 2026-07-30 PlS Planned sale
Mokari Atabak

Chief Financial Officer

Officer
1,001 -5.8%
120.67
US$120,796 		1,001 -5.8% 120.67 US$120,796
2026-08-03 2026-07-30 PlS Planned sale
Mokari Atabak

Chief Financial Officer

Officer
8,103 -32.1%
119.95
US$971,939 		8,103 -32.1% 119.95 US$971,939
2026-08-03 2026-07-30 PlS Planned sale
Mokari Atabak

Chief Financial Officer

Officer
4,783 -15.9%
118.73
US$567,908 		4,783 -15.9% 118.73 US$567,908
2026-08-03 2026-07-30 PlS Planned sale
Mokari Atabak

Chief Financial Officer

Officer
8,267 -21.6%
117.93
US$974,951 		8,267 -21.6% 117.93 US$974,951
2026-08-03 2026-07-30 PlS Planned sale
Mokari Atabak

Chief Financial Officer

Officer
7,089 -15.6%
116.96
US$829,102 		7,089 -15.6% 116.96 US$829,102
2026-08-03 2026-07-30 PlS Planned sale
Mokari Atabak

Chief Financial Officer

Officer
14,222 -23.9%
115.87
US$1,647,859 		14,222 -23.9% 115.87 US$1,647,859
2026-08-03 2026-07-30 PlS Planned sale
Mokari Atabak

Chief Financial Officer

Officer
15,477 -20.6%
114.96
US$1,779,237 		15,477 -20.6% 114.96 US$1,779,237
2026-08-03 2026-07-30 PlS Planned sale
Mokari Atabak

Chief Financial Officer

Officer
4,700 -5.9%
113.18
US$531,941 		4,700 -5.9% 113.18 US$531,941
2026-08-03 2026-07-30 PlS Planned sale
Mokari Atabak

Chief Financial Officer

Officer
600 -0.7%
110.95
US$66,570 		600 -0.7% 110.95 US$66,570
2026-08-03 2026-07-30 PlS Planned sale
Mokari Atabak

Chief Financial Officer

Officer
2,202 -2.7%
110.03
US$242,282 		2,202 -2.7% 110.03 US$242,282
2026-08-03 2026-07-30 PlS Planned sale
Mokari Atabak

Chief Financial Officer

Officer
400 -0.5%
108.46
US$43,384 		400 -0.5% 108.46 US$43,384
2026-08-03 2026-07-30 PlS Planned sale
Mokari Atabak

Chief Financial Officer

Officer
8,956 -9.7%
106.96
US$957,892 		8,956 -9.7% 106.96 US$957,892
2026-08-03 2026-07-30 PlS Planned sale
Mokari Atabak

Chief Financial Officer

Officer
4,200 -4.4%
105.54
US$443,248 		4,200 -4.4% 105.54 US$443,248
2026-07-30 2026-07-30 PrS Proposed sale
Mokari Atabak

Officer

Officer
40,000
114.71
US$4,588,556 		40,000 114.71 US$4,588,556
2026-07-17 2026-07-15 PlS Planned sale
WILSON JAMES N
Non-Executive Director
1,978 -0.2%
89.49
US$177,007 		1,978 -0.2% 89.49 US$177,007
2026-07-17 2026-07-15 PlS Planned sale
WILSON JAMES N
Non-Executive Director
2,974 -0.3%
88.81
US$264,122 		2,974 -0.3% 88.81 US$264,122
2026-07-17 2026-07-15 PlS Planned sale
WILSON JAMES N
Non-Executive Director
3,969 -0.4%
87.74
US$348,223 		3,969 -0.4% 87.74 US$348,223
2026-07-17 2026-07-15 PlS Planned sale
WILSON JAMES N
Non-Executive Director
1,079 -0.1%
86.78
US$93,633 		1,079 -0.1% 86.78 US$93,633
2026-07-17 2026-07-15 PlS Planned sale
Mokari Atabak

Chief Financial Officer

Officer
101 -0.6%
89.43
US$9,032 		101 -0.6% 89.43 US$9,032
Explore more

More insider trading research around Corcept Therapeutics Incorporated

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America